Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

ClinicalTrials.gov ID: NCT02131272

Public ClinicalTrials.gov record NCT02131272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin

Study identification

NCT ID
NCT02131272
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
42 participants

Conditions and interventions

Interventions

  • Diet/exercise Behavioral
  • Insulin NPH Drug
  • Insulin detemir Drug

Behavioral · Drug

Eligibility (public fields only)

Age range
10 Years to 18 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 10, 2014
Primary completion
Jun 13, 2016
Completion
Jun 13, 2016
Last update posted
Sep 9, 2018

2014 – 2016

United States locations

U.S. sites
23
U.S. states
15
U.S. cities
22
Facility City State ZIP Site status
Novo Nordisk Investigational Site Tucson Arizona 85724
Novo Nordisk Investigational Site Los Angeles California 90027
Novo Nordisk Investigational Site Jacksonville Florida 32207
Novo Nordisk Investigational Site Jacksonville Florida 32256
Novo Nordisk Investigational Site Pembroke Pines Florida 33026
Novo Nordisk Investigational Site Tallahassee Florida 32308
Novo Nordisk Investigational Site Atlanta Georgia 30322
Novo Nordisk Investigational Site Reisterstown Maryland 20011
Novo Nordisk Investigational Site Silver Spring Maryland 20910
Novo Nordisk Investigational Site Las Vegas Nevada 89148
Novo Nordisk Investigational Site Buffalo New York 14203
Novo Nordisk Investigational Site Cleveland Ohio 44195-0001
Novo Nordisk Investigational Site Toledo Ohio 43606
Novo Nordisk Investigational Site Hershey Pennsylvania 17033
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224
Novo Nordisk Investigational Site Providence Rhode Island 02903
Novo Nordisk Investigational Site Columbia South Carolina 29203
Novo Nordisk Investigational Site Memphis Tennessee 38119
Novo Nordisk Investigational Site Amarillo Texas 79106
Novo Nordisk Investigational Site Edinburg Texas 78539
Novo Nordisk Investigational Site Norfolk Virginia 23507
Novo Nordisk Investigational Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 59 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02131272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 9, 2018 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02131272 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →